Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in Spain
- PMID: 35313009
- PMCID: PMC9111861
- DOI: 10.1111/eci.13771
Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in Spain
Abstract
Background: To evaluate the impact of COVID-19 lockdown on glycaemic control and diabetes follow-up in a Spanish metropolitan area with a total general population of 340,000.
Methods: A retrospective real-world study comparing HbA1c testing, an indicator of diabetes control, and mean HbA1c during different COVID-19 restriction periods in 2020 (full lockdown, post-lockdown, partial lockdown) with the same periods in 2019. HbA1c testing was analysed per study period and according to gender, age and clinical setting. Associations between HbA1c testing and different covariables were investigated using logistic regression analysis. Changes in HbA1c were evaluated by repeated measures multivariate analysis of variance (ANOVA).
Results: During full lockdown, 6847 individuals, of which 56.7% were over 65 and 6.5% below 40, were tested for HbA1c compared to 14,180 in 2019 (OR 0.47, 95% CI:0.46-0.49). Reduction in HbA1c testing was greater among older individuals (OR 0.44, 95% CI:0.42-0.45). No differences were observed for post-lockdown (OR 1.01, 95% CI:0.99-1.04). During partial lockdown, 10,816 individuals had at least one HbA1c measured compared to 12,749 in 2019 (OR 0.84, 95% CI:0.82-0.87). Mean HbA1c during full lockdown was 7.26% (±1.06) compared to 7.50% (±1.14) in 2019 (p < .0001). For gender and across all age groups, HbA1c levels were lower during full lockdown. HbA1c changes were not significantly different during post-lockdown and partial lockdown.
Conclusions: COVID-19 restriction measures affected HbA1c testing. During complete lockdown, HbA1c testing decreased by half across all gender and age groups. No deleterious effect on glycaemic control was observed during lockdown and post-lockdown among those tested.
Keywords: COVID-19; HbA1c; diabetes control; lockdown.
© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Conflict of interest statement
F.J.A.B. has served as a consultant/advisor for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, LifeScan, MannKind Co., Medtronic, Menarini, Merck, Novartis, Novo Nordisk and Sanofi, and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, LifeScan, Eli Lilly, Madaus, Medtronic, Menarini, Merck, Novartis, Novo Nordisk and Sanofi and has received grant support from Novo Nordisk and Sanofi. A. P., C. Q. T., J. G. and J. T. R. have no relevant conflict of interest to disclose.
References
-
- World Health Organization . Rolling updates on coronavirus disease (COVID‐19): WHO characterizes COVID‐19 as a pandemic. WHO. https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/events‐a.... Updated July 31, 2020. Accessed July 31, 2021.
-
- Pomares Gómez FJ, Fernando de la Torre A, Morillas Ariño C, et al. Estrategia de diabetes de la Comunitat Valenciana 2017–2021. Generalitat Valenciana; 2017. http://www.san.gva.es/documents/156344/7167642/Estrategia+de+diabetes+CV.... Accessed January 15, 2022.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
